Related Experiment Video

Updated: Nov 27, 2025

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
11:00

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Published on: September 18, 2017

10.4K

RCAN1 in cardiovascular diseases: molecular mechanisms and a potential therapeutic target

Shuai Wang1,2, Yuqing Wang1,2,3, Kaixin Qiu1,2,3

  • 1Shandong Collaborative Innovation Center for Diagnosis, Treatment and Behavioral Interventions of Mental Disorders, Institute of Mental Health, Jining Medical University, Jianshe South Road No. 45, Rencheng District, Jining, 272013, Shandong, China.

Molecular Medicine (Cambridge, Mass.)
|December 3, 2020
PubMed

Insights

Regulator of calcineurin 1 (RCAN1) plays a dual role in cardiovascular diseases (CVDs). Reducing RCAN1 offers protection against atherosclerosis and myocardial injury, highlighting its therapeutic potential.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Biochemistry

Background:

  • Cardiovascular diseases (CVDs) represent a significant global health burden, necessitating deeper understanding of disease mechanisms.
  • Regulator of calcineurin 1 (RCAN1) is implicated in cardiovascular system development, maintenance, and disease pathogenesis.

Purpose of the Study:

  • To review the regulation, function, and dysregulation of RCAN1 in the context of CVDs.
  • To discuss the beneficial effects of RCAN1 modulation in various cardiovascular conditions and explore therapeutic strategies.

Main Methods:

  • Literature review focusing on RCAN1's role in cardiovascular pathophysiology.
  • Analysis of studies investigating RCAN1's impact on atherosclerosis, myocardial ischemia/reperfusion injury, hypertrophy, and aortic rupture.

Main Results:

  • RCAN1 reduction protects against atherosclerosis by limiting oxidized low-density lipoprotein uptake.
  • RCAN1 exhibits protective effects in myocardial ischemia/reperfusion injury, hypertrophy, and intramural hematoma/aortic rupture via mitochondrial function and inhibition of calcineurin/Rho kinase.

Conclusions:

  • RCAN1's multifaceted role in CVDs presents both challenges and therapeutic opportunities.
  • Targeting RCAN1 modulation could offer novel treatment strategies for various cardiovascular diseases.

Keywords:
Cardiovascular diseaseRegulator of calcineurin 1Therapeutic potential

More Related Videos

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

1.9K
Dynamic Continuous Blood Extraction from Rat Heart via Noninvasive Microdialysis Technique04:52

Dynamic Continuous Blood Extraction from Rat Heart via Noninvasive Microdialysis Technique

Published on: September 13, 2022

2.6K

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
688
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
209
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.0K
Regulation of the Cardiovascular System01:27

Regulation of the Cardiovascular System

The regulation of the cardiovascular system allows the body to adapt to various demands and maintain homeostasis.
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
3.0K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
258
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
686